Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. | Journal of Psychopharmacology | 16 January 2020
Ayahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers.
Murphy-Beiner, A., & Soar, K. | Psychopharmacology | 11 January 2020
A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamine
Palamar, J. J., & Acosta, P. | Clinical and Experimental | 07 January 2020
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. | Psychiatry Research | 2 January 2020
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.
Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., & de Wit, H. | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging | 20 December 2019
Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers.
Family, N., Maillet, E. L., Williams, L. T., Krediet, E., Carhart-Harris, R. L., Williams, T. M., ... & Raz, S. | Psychopharmacology | 18 December 2019
Neurotrophic mechanisms of psychedelic therapy
Corne, R., & Mongeau, R. | Biologie aujourd'hui | 12 December 2019
Neuropharmacological modulation of the aberrant bodily self through psychedelics
Ho, J. T., Preller, K. H., & Lenggenhager, B. | Neuroscience & Biobehavioral Reviews | 6 December 2019
Modulation of Social Cognition via Hallucinogens and “Entactogens”.
Preller, K. H., & Vollenweider, F. X. | Frontiers in Psychiatry | 3 December 2019
Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
dos Santos, R. G., & Hallak, J. E. C. | Neuroscience & Biobehavioral Reviews | 3 December 2019
Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
Moreton, S. G., Szalla, L., Menzies, R. E., & Arena, A. F. | Psychopharmacology | 29 November 2019
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Lea, T., Amada, N., Jungaberle, H., Schecke, H., & Klein, M. | International Journal of Drug Policy | 25 November 2019
Psilocybin-assisted therapy for depression: How do we advance the field?
Meikle, S. E., Liknaitzky, P., Rossell, S. L., Ross, M., Strauss, N., Thomas, N., ... & Castle, D. J. | Australian & New Zealand Journal of Psychiatry | 22 November 2019
The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial.
Zeifman, R., Palhano-Fontes, F., Hallak, J., Nunes, E. A., Maia-de-Oliveira, J. P., & de Araujo, D. B. | Frontiers in Pharmacology | 19 November 2019
High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans.
Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. | Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists | 1 November 2019
Searching for Treatments for Cocaine Use Disorder: The Quest Continues.
Brady, K. T. | American Journal of Psychiatry | 1 November 2019
Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.
dos Santos, R. G., Bouso, J. C., & Hallak, J. E. | BMC psychiatry | 28 October 2019
Esketamine Prevents Treatment-Resistant Depression Relapse.
Slomski, A. | Jama | 22 October 2019
The psychedelic renaissance: the next trip for psychiatry?
Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. | Irish journal of psychological medicine | 23 September 2019
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers
Hutten, N. R., Mason, N. L., Dolder, P. C., & Kuypers, K. P. | Frontiers in psychiatry | 13 September 2019
The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression
O’Brien, B., Lijffijt, M., Wells, A., Swann, A. C., & Mathew, S. J. | Pharmaceuticals | 11 September 2019
Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada
Argento, E., Capler, R., Thomas, G., Lucas, P., & Tupper, K. W. | Drug and alcohol review | 5 September 2019
Hallucinogens and Their Therapeutic Use: A Literature Review
BEGOLA, M. J., & SCHILLERSTROM, J. E. | Journal of Psychiatric Practice | September 2019
Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement.
Wang, M., Xiong, Z., Su, B., Wang, L., Li, Z., Yang, Y., & Fang, J. | Journal of clinical pharmacy and therapeutics | 30 August 2019
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., ... & Schatzberg, A. F. | Molecular psychiatry | 29 August 2019